Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Aptivus
Aptivus 250 mg soft capsules · Abschnitt 4.5 · PDF-Seite 19
HOS-114841 · Präparat HOS-094169
Antacids
aluminium- and Tipranavir Cmax ↓ 25% Dosing of Aptivus, co-
magnesium-based antacid Tipranavir AUC ↓ 27% administered with low dose
QD ritonavir, with antacids should be
Mechanism unknown separated by at least a two hours
time interval.
Proton pump inhibitors (PPIs)
Omeprazole 40 mg QD Omeprazole Cmax ↓ 73% The combined use of Aptivus, co-
Omeprazole AUC ↓ 70% administered with low dose
ritonavir, with either omeprazole
Similar effects were observed for or esomeprazole is not
the S-enantiomer, esomeprazole. recommended (see section 4.4). If
unavoidable, upward dose
Induction of CYP 2C19 by adjustments for either
tipranavir/r omeprazole or esomeprazole may
be considered based on clinical
Tipranavir ↔ response to therapy. There are no
data available indicating that
omeprazole or esomeprazole dose
adjustments will overcome the
observed pharmacokinetic
interaction. Recommendations
for maximal doses of omeprazole
or esomeprazole are found in the
corresponding product
information. No tipranavir with
ritonavir dose adjustment is
required.
Lansoprazole Based on the metabolic profiles The combined use of Aptivus, co-
Pantoprazole of tipranavir/r and the proton administered with low dose
Rabeprazole pump inhibitors, an interaction ritonavir, with proton pump
No interaction study can be expected. As a result of inhibitors is not recommended
performed CYP3A4 inhibition and (see section 4.4). If the co-
CYP2C19 induction by administration is judged
tipranavir/r, lansoprazole and unavoidable, this should be done
pantoprazole plasma under close clinical monitoring.
concentrations are difficult to
predict. Rabeprazole plasma
concentrations might decrease as
a result of induction of CYP2C19
by tipranavir/r.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) rabeprazole (HOS-114843) esomeprazole (HOS-087944) pantoprazole (HOS-085167) ritonavir (HOS-084521) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-23T09:35:00Z · SHA-256 1c396190f98e89933229f2261b0e436bd43dac9c1de8e2dacaa36a755dc06dce · Passage c99aa431c7e3f77cb519d4da2aced0a374d801c9c352b5d32534ed58e4e72798 · Zeichen 45182–48575 im Abschnitt
Gegenanzeigen · Edurant
EDURANT 25 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 3–4
HOS-213920 · Präparat HOS-155234
3
- proton pump inhibitors, such as omeprazole, esomeprazole, lansoprazole, pantoprazole,
rabeprazole
- the systemic glucocorticoid dexamethasone, except as a single dose treatment
- St John’s wort (Hypericum perforatum).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) rabeprazole (HOS-114843) esomeprazole (HOS-087944) pantoprazole (HOS-085167) dexamethasone (HOS-084535) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-04-11T14:54:00Z · SHA-256 c02ae8018d7111133de16dc7b25339ee095e696ed781b3973764a15d8d998fed · Passage 3d8f70a8df24ad2092c33706bc42df15106006c755f856c2e33f2b424c87eb4f · Zeichen 564–804 im Abschnitt
Gegenanzeigen · Edurant
EDURANT 2.5 mg dispersible tablets · Abschnitt 4.3 · PDF-Seite 27
HOS-213989 · Präparat HOS-155234
EDURANT should not be co-administered with the following medicinal products, as significant
decreases in rilpivirine plasma concentrations may occur (due to CYP3A enzyme induction or gastric
pH increase), which may result in loss of therapeutic effect of EDURANT (see section 4.5):
- the anticonvulsants carbamazepine, oxcarbazepine, phenobarbital, phenytoin
- the antimycobacterials rifampicin, rifapentine
- proton pump inhibitors, such as omeprazole, esomeprazole, lansoprazole, pantoprazole,
rabeprazole
- the systemic glucocorticoid dexamethasone, except as a single dose treatment
- St John’s wort (Hypericum perforatum).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) rabeprazole (HOS-114843) esomeprazole (HOS-087944) phenobarbital (HOS-085617) carbamazepine (HOS-085618) pantoprazole (HOS-085167) dexamethasone (HOS-084535) rifapentine (HOS-116386) oxcarbazepine (HOS-110224) phenytoin (HOS-084531) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-04-11T14:54:00Z · SHA-256 c02ae8018d7111133de16dc7b25339ee095e696ed781b3973764a15d8d998fed · Passage d98981b21a5ac22277f5deb9f4fdca02f3afbd0faa096feb83283fb58697e8d1 · Zeichen 93–746 im Abschnitt
Wechselwirkungen · Edurant
EDURANT 25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-213954 · Präparat HOS-155234
(reduced absorption due to gastric
pH increase)
Lansoprazole Not studied. Significant decreases
Rabeprazole in rilpivirine plasma concentrations
Pantoprazole are expected.
Esomeprazole
(reduced absorption due to gastric
pH increase)
H2-RECEPTOR ANTAGONISTS
Famotidine*# rilpivirine AUC ↓ 9% The combination of rilpivirine and
40 mg single dose taken rilpivirine Cmin NA H2-receptor antagonists should be used
12 hours before rilpivirine Cmax ↔ with particular caution. Only
rilpivirine H2-receptor antagonists that can be
Famotidine*# rilpivirine AUC ↓ 76% dosed once daily should be used.
40 mg single dose taken rilpivirine Cmin NA A strict dosing schedule, with intake of
2 hours before rilpivirine rilpivirine Cmax ↓ 85% H2-receptor antagonists at least
12 hours before or at least 4 hours
(reduced absorption due to gastric after rilpivirine should be used.
pH increase)
Famotidine*# rilpivirine AUC ↑ 13%
40 mg single dose taken rilpivirine Cmin NA
4 hours after rilpivirine rilpivirine Cmax ↑ 21%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) rabeprazole (HOS-114843) esomeprazole (HOS-087944) pantoprazole (HOS-085167) famotidine (HOS-112087)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-04-11T14:54:00Z · SHA-256 c02ae8018d7111133de16dc7b25339ee095e696ed781b3973764a15d8d998fed · Passage 5750a8dd531929b2deb157a6729b51df0f69271ef3f861e7be5ef6ef2561c556 · Zeichen 12653–14207 im Abschnitt
Wechselwirkungen · Edurant
EDURANT 2.5 mg dispersible tablets · Abschnitt 4.5 · PDF-Seite 31
HOS-214008 · Präparat HOS-155234
(reduced absorption due to gastric
pH increase)
Lansoprazole Not studied. Significant decreases
Rabeprazole in rilpivirine plasma concentrations
Pantoprazole are expected.
Esomeprazole
(reduced absorption due to gastric
pH increase)
H2-RECEPTOR ANTAGONISTS
Famotidine*# rilpivirine AUC ↓ 9% The combination of rilpivirine and
40 mg single dose taken rilpivirine Cmin NA H2-receptor antagonists should be used
12 hours before rilpivirine Cmax ↔ with particular caution. Only
rilpivirine H2-receptor antagonists that can be
Famotidine*# rilpivirine AUC ↓ 76% dosed once daily should be used.
40 mg single dose taken rilpivirine Cmin NA A strict dosing schedule, with intake of
2 hours before rilpivirine rilpivirine Cmax ↓ 85% H2-receptor antagonists at least
12 hours before or at least 4 hours
(reduced absorption due to gastric after rilpivirine should be used.
pH increase)
Famotidine*# rilpivirine AUC ↑ 13%
40 mg single dose taken rilpivirine Cmin NA
4 hours after rilpivirine rilpivirine Cmax ↑ 21%
Cimetidine Not studied.
Nizatidine
Ranitidine (reduced absorption due to gastric
pH increase)
ANTACIDS
Antacids (e.g., Not studied. Significant decreases The combination of rilpivirine and
aluminium or magnesium in rilpivirine plasma concentrations antacids should be used with particular
hydroxide, calcium are expected. caution. Antacids should only be
carbonate) administered either at least 2 hours
(reduced absorption due to gastric before or at least 4 hours after
pH increase) rilpivirine.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) nizatidine (HOS-138496) rabeprazole (HOS-114843) esomeprazole (HOS-087944) cimetidine (HOS-085835) pantoprazole (HOS-085167) famotidine (HOS-112087) calcium (HOS-085615) ranitidine (HOS-085660) magnesium (HOS-085165)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-04-11T14:54:00Z · SHA-256 c02ae8018d7111133de16dc7b25339ee095e696ed781b3973764a15d8d998fed · Passage 127a046a3ba0f0f2919bad57eab9493f739a4627df3219ad6f8640932758cd01 · Zeichen 11316–13658 im Abschnitt
Gegenanzeigen · Eviplera
Eviplera 200 mg/25 mg/245 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 4
HOS-214348 · Präparat HOS-155326
Eviplera should not be co-administered with the following medicinal products as significant decreases
in rilpivirine plasma concentrations may occur (due to cytochrome P450 [CYP]3A enzyme induction
or gastric pH increase), which may result in loss of therapeutic effect of Eviplera:
• the anticonvulsants carbamazepine, oxcarbazepine, phenobarbital, phenytoin
• the antimycobacterials rifampicin, rifapentine
• proton pump inhibitors, such as omeprazole, esomeprazole, lansoprazole, pantoprazole,
rabeprazole
• the systemic glucocorticoid dexamethasone, except as a single dose treatment
• St. John’s wort (Hypericum perforatum)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) rabeprazole (HOS-114843) esomeprazole (HOS-087944) phenobarbital (HOS-085617) carbamazepine (HOS-085618) pantoprazole (HOS-085167) dexamethasone (HOS-084535) rifapentine (HOS-116386) oxcarbazepine (HOS-110224) phenytoin (HOS-084531) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-06-19T11:57:00Z · SHA-256 3873fd554f54608c25be65a5e155834d2d4981603221b5f24abb68e92e1af40e · Passage aa4f2e1664ff43fed53d47e187bf01139fd64995942111c422ec307cb98b6fce · Zeichen 94–760 im Abschnitt
Wechselwirkungen · Erivedge
Erivedge 150 mg hard capsules · Abschnitt 4.5 · PDF-Seite 6
HOS-127628 · Präparat HOS-096441
Clinically significant pharmacokinetic (PK) interactions between vismodegib and pH elevating agents
are not expected. Results from a clinical study demonstrated a 33% decrease in vismodegib unbound
drug concentrations after 7 days co-treatment with 20 mg rabeprazole (a proton pump inhibitor) given
2 hours before each vismodegib administration. This interaction is not expected to be clinically
significant.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rabeprazole (HOS-114843)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-05T17:22:00Z · SHA-256 7c5947771fc6ba6c7e20988015625540b8e7a6e41e1e343dfb62d42b9baa912f · Passage c477f4a88f832666f4a6c647f8e1f288ac2ec8959e9f9d7b9feb768e00e2a62b · Zeichen 57–465 im Abschnitt
Wechselwirkungen · Ibrance
IBRANCE 75 mg hard capsules IBRANCE 100 mg hard capsules IBRANCE 125 mg hard capsules · Abschnitt 4.5 · PDF-Seite 7
HOS-132441 · Präparat HOS-097230
Under fed conditions (intake of a moderate-fat meal), coadministration of multiple doses of the proton
pump inhibitor (PPI) rabeprazole with a single dose of 125 mg IBRANCE decreased palbociclib Cmax
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rabeprazole (HOS-114843)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-07T16:43:00Z · SHA-256 73a98bcaed2e5b347266ff9f037099270b545348fdf729a2479eedc3e06fd319 · Passage 112e6e4b8b3ebd4a68c571bba39393e507776de5d267ecd875281614b49aad15 · Zeichen 1735–1934 im Abschnitt
Wechselwirkungen · Ibrance
IBRANCE 75 mg hard capsules IBRANCE 100 mg hard capsules IBRANCE 125 mg hard capsules · Abschnitt 4.5 · PDF-Seite 8
HOS-132443 · Präparat HOS-097230
Under fasting conditions, the coadministration of multiple doses of the PPI rabeprazole with a single
dose of 125 mg IBRANCE decreased palbociclib AUCinf and Cmax by 62% and 80%, respectively.
Therefore, IBRANCE should be taken with food, preferably a meal (see sections 4.2 and 5.2).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rabeprazole (HOS-114843)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-07T16:43:00Z · SHA-256 73a98bcaed2e5b347266ff9f037099270b545348fdf729a2479eedc3e06fd319 · Passage 193d9fa46de57b9260cb5e5e0f5068e54260396105cdadbff060e009a9deb1c2 · Zeichen 2114–2398 im Abschnitt
Wechselwirkungen · Ibrance
IBRANCE 75 mg film-coated tablets IBRANCE 100 mg film-coated tablets IBRANCE 125 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 31
HOS-132497 · Präparat HOS-097230
Coadministration of multiple doses of the PPI rabeprazole with a single 125 mg IBRANCE tablet
under fasted conditions had no effect on the rate and extent of absorption of palbociclib when
compared to a single 125 mg IBRANCE tablet administered alone.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rabeprazole (HOS-114843)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-07T16:43:00Z · SHA-256 73a98bcaed2e5b347266ff9f037099270b545348fdf729a2479eedc3e06fd319 · Passage 7d6f2b7854bd444998fa798eb9985adab09aa1d6e6abd83ecb456665609c8d8d · Zeichen 1739–1990 im Abschnitt
Wechselwirkungen · Symtuza
Symtuza 800 mg/150 mg/200 mg/10 mg film-coated tablets Symtuza 675 mg/150 mg/200 mg/10 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 17–18
HOS-138500 · Präparat HOS-098200
17
PROTON PUMP INHIBITORS
Dexlansoprazole Based on theoretical Symtuza can be co-administered
Esomeprazole considerations, no mechanistic with proton pump inhibitors
Lansoprazole interaction is expected. without dose adjustments.
Omeprazole
Pantoprazole
Rabeprazole
SEDATIVES/HYPNOTICS
Buspirone Based on theoretical considerations Clinical monitoring is
Clorazepate DRV/COBI is expected to increase recommended when
Diazepam these sedative/hypnotic plasma co-administering Symtuza with
Estazolam concentrations. these sedatives/hypnotics and a
Flurazepam (CYP3A inhibition) lower dose of the
Midazolam (parenteral) sedative/hypnotic should be
Zolpidem considered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) rabeprazole (HOS-114843) estazolam (HOS-086165) esomeprazole (HOS-087944) pantoprazole (HOS-085167) clorazepate (HOS-086164) diazepam (HOS-085904) zolpidem (HOS-086327) buspirone (HOS-086325) dexlansoprazole (HOS-138501) flurazepam (HOS-086166) midazolam (HOS-086167) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-16T11:21:00Z · SHA-256 542f840b29cc7afaff9940b20511550e8d35031b33d95efd774fd49f70f7819d · Passage d66918b1ab817bed50d64727b6ed8e70c3661e6e6c213975acff37740c998350 · Zeichen 42940–44015 im Abschnitt
Gegenanzeigen · Juluca
Juluca 50 mg/25 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 3
HOS-138646 · Präparat HOS-098240
Co-administration with the following medicinal products:
- fampridine (also known as dalfampridine);
- carbamazepine, oxcarbazepine, phenobarbital, phenytoin;
- rifampicin, rifapentine;
- proton pump inhibitors, such as omeprazole, esomeprazole, lansoprazole, pantoprazole, rabeprazole;
- systemic dexamethasone, except as a single dose treatment;
- St John's wort (Hypericum perforatum).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) rabeprazole (HOS-114843) esomeprazole (HOS-087944) phenobarbital (HOS-085617) carbamazepine (HOS-085618) pantoprazole (HOS-085167) dexamethasone (HOS-084535) dalfampridine (HOS-124191) rifapentine (HOS-116386) oxcarbazepine (HOS-110224) phenytoin (HOS-084531) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-14T16:39:00Z · SHA-256 0933317665b752128ea731fe5d180ec3ebff8bd69929c361b4010ae11184c9c5 · Passage 9174ae712b2df8e1079fcece69b45cda4a99f625ece4256ab47b980d2ebdfffe · Zeichen 94–482 im Abschnitt
Wechselwirkungen · Juluca
Juluca 50 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10
HOS-138687 · Präparat HOS-098240
Fluconazole Rilpivirine ↑
Itraconazole Not studied. May cause an
Isavuconazole increase in the
Posaconazole plasma concentrations of
Voriconazole/ rilpivirine
Rilpivirine (inhibition of CYP3A
enzymes).
Herbal products
St. John’s wort/ Dolutegravir Co-administration may cause significant decreases
Dolutegravir Not studied. Decrease in rilpivirine plasma concentrations. This may
expected due to induction of result in loss of therapeutic effect of
UGT1A1 and CYP3A dolutegravir/rilpivirine. Co-administration of
enzymes, a similar reduction dolutegravir/rilpivirine with St. John’s wort is
in exposure as observed contraindicated (see section 4.3).
with carbamazepine is
expected.
St. John’s wort/
Rilpivirine Rilpivirine
Not studied. Significant
decreases in rilpivirine
plasma concentrations are
expected
(induction of CYP3A
enzymes).
Potassium channel blockers
Fampridine (also Fampridine Co-administration of dolutegravir has the potential
known as to cause seizures due to increased fampridine
dalfampridine)/ plasma concentration via inhibition of OCT2
Dolutegravir transporter; co-administration has not been studied.
Fampridine co-administration with
dolutegravir/rilpivirine is contraindicated (see
section 4.3).
Proton pump inhibitors
Omeprazole Dolutegravir Co-administration may significantly decrease
Lansoprazole (Not studied) rilpivirine plasma concentration. This may result in
Rabeprazole loss of therapeutic effect of
Pantoprazole dolutegravir/rilpivirine. Co-administration of
Esomeprazole/ dolutegravir/rilpivirine with proton pump
Dolutegravir inhibitors is contraindicated (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) isavuconazole (HOS-085186) rabeprazole (HOS-114843) esomeprazole (HOS-087944) carbamazepine (HOS-085618) pantoprazole (HOS-085167) voriconazole (HOS-084524) itraconazole (HOS-084516) dalfampridine (HOS-124191) fluconazole (HOS-087945) potassium (HOS-086929) posaconazole (HOS-085622) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-14T16:39:00Z · SHA-256 0933317665b752128ea731fe5d180ec3ebff8bd69929c361b4010ae11184c9c5 · Passage a31f2642580d15bddbc8923f96075e21d607d5433d01b4ad8e687e24731abda2 · Zeichen 12137–14762 im Abschnitt
Wechselwirkungen · Juluca
Juluca 50 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11
HOS-138690 · Präparat HOS-098240
Lansoprazole Rilpivirine
Rabeprazole Not studied. Significant
Pantoprazole decreases in rilpivirine
Esomeprazole/ plasma concentrations are
Rilpivirine expected
(reduced absorption due to
gastric pH increase).
H2-recepter antagonists
Famotidine Dolutegravir The combination of dolutegravir/rilpivirine and
Cimetidine (Not studied) H2-receptor antagonists should be used with
Nizatidine particular caution. Only H2-receptor antagonists
Ranitidine/ that can be dosed once daily should be used.
Dolutegravir
H2-receptor antagonists should be taken well
Famotidine/ Rilpivirine separated in time from the administration of
Rilpivirine1,2 AUC ↓ 9% dolutegravir/rilpivirine (minimum 4 hours after or
40 mg single dose Cmin NA 12 hours before)
taken 12 hours before Cmax ↔
rilpivirine
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) nizatidine (HOS-138496) rabeprazole (HOS-114843) esomeprazole (HOS-087944) cimetidine (HOS-085835) pantoprazole (HOS-085167) famotidine (HOS-112087) ranitidine (HOS-085660)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-14T16:39:00Z · SHA-256 0933317665b752128ea731fe5d180ec3ebff8bd69929c361b4010ae11184c9c5 · Passage ea9028ca3d0fa3d4c503c1b3af0236bf88a7f581c3738dab63a63d57e45bc310 · Zeichen 15199–16371 im Abschnitt
Wechselwirkungen · Vizimpro
Vizimpro 15 mg film-coated tablets Vizimpro 30 mg film-coated tablets Vizimpro 45 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-141895 · Präparat HOS-098712
The aqueous solubility of dacomitinib is pH dependent, with low (acidic) pH resulting in higher
solubility. Data from a study in 24 healthy subjects indicated that co-administration of a single 45 mg
dacomitinib dose with the PPI rabeprazole 40 mg once daily for 7 days decreased dacomitinib Cmax,
AUC0-96h (area under the concentration-time curve from time 0 to 96 hours), and AUCinf (AUC from
time 0 to infinity) (n=14) by approximately 51%, 39%, and 29%, respectively, when compared to a
single 45 mg dose of dacomitinib administered alone. PPIs should be avoided while receiving
treatment with dacomitinib (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rabeprazole (HOS-114843) dacomitinib (HOS-141892)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-12-17T10:45:00Z · SHA-256 6423421a559569edb50e690c7adfb2244dadfdef9ead0c56c0d6b33fb1c654f0 · Passage 9e1c3b9fde428c15dccee33705ad20436804d18c6110bb2ef46b8666a0abb8b4 · Zeichen 71–699 im Abschnitt
Wechselwirkungen · Emcitate
Emcitate 350 microgram dispersible tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-145386 · Präparat HOS-099344
Proton pump inhibitors (PPIs)
Co-administration with PPIs may cause a decrease in the absorption of the thyroid hormones, due to
the increase of the intragastric pH caused by PPIs such as omeprazole, esomeprazole, pantoprazole,
rabeprazole and lansoprazole. Serum concentrations of T3 should be monitored and dose adjustment
of tiratricol considered when initiating, changing or discontinuing PPI treatment.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) rabeprazole (HOS-114843) esomeprazole (HOS-087944) pantoprazole (HOS-085167) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-11T10:55:11Z · SHA-256 f1406017bf71ca6ed21c19c56ad9b2f42db03a6c0c95a8b1a995b810587719f2 · Passage f801ef17438c9ed33d30d077ff1f9b5a47ec71bff15f7bcd4ca8fef0f960bd66 · Zeichen 1031–1438 im Abschnitt
Wechselwirkungen · Calquence
Calquence 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 47
HOS-146071 · Präparat HOS-099443
No clinically significant differences in acalabrutinib pharmacokinetics were observed when a 100 mg
acalabrutinib tablet was used concomitantly with a proton pump inhibitor (rabeprazole 20 mg twice daily
for 3 days). Acalabrutinib tablets can be co-administered with gastric acid reducing agents (proton pump
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rabeprazole (HOS-114843) acalabrutinib (HOS-145966)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-07T14:45:00Z · SHA-256 23823231ddd2d9d6c6ed4788276579f41dd0c4dfc8ca67fef193be872eb62325 · Passage a359a1ee1e85426f5adc02f1112a729f9d3095392d374873d449c1b8075023fc · Zeichen 1880–2188 im Abschnitt
Wechselwirkungen · Sotyktu
SOTYKTU 6 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-149256 · Präparat HOS-100020
Medicinal products that are inhibitors or inducers of CYP enzymes or transporters such as
cyclosporine (dual P-gp/breast cancer resistance protein [BCRP] inhibitor), fluvoxamine (strong
CYP 1A2 inhibitor), ritonavir (moderate CYP 1A2 inducer), diflunisal (UGT 1A9 inhibitor),
pyrimethamine (OCT1 inhibitor), famotidine (H2 receptor antagonist) or rabeprazole (proton pump
inhibitor) do not meaningfully affect plasma deucravacitinib exposures (see section 5.2).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rabeprazole (HOS-114843) famotidine (HOS-112087) diflunisal (HOS-127089) ritonavir (HOS-084521) fluvoxamine (HOS-085908) pyrimethamine (HOS-088523) cyclosporine (HOS-084512)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-03T18:15:00Z · SHA-256 9ba2af895eb769b0e134e9b62a0e549462d3c3401ee20e2f9d271718a8dad081 · Passage 84326d04fd5262ff93b11039d13229179c5aa7006e8a9a4f808e14fec001f5f9 · Zeichen 758–1219 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.